5519 POSTER

Proton beam therapy for nasal cavity and paranasal sinus malignancies

T. Ogino, M. Kawashima, S. Zenda, S. Arahira, R. Kohno, T. Nishio. *National Cancer Center Hospital East, Division of Radiation Oncology, Kashiwa, Japan*

Background: Advanced malignancy of nasal cavity and paranasal sinus shows high rate of local failure, and is difficult to deliver enough X-ray radiation doses by conventional technique because of its proximity to critical organs such as optic pathway and brain stem. Proton beam therapy (PBT) can provide better dose distribution because of its physical characteristics, and is deemed to be a feasible treatment modality. We retrospectively reviewed our experience to analyze the feasibility and efficacy of PBT for nasal cavity and paranasal sinus malignancies.
Materials and Methods: Between 1999–2006, 93 patients with nasal or paranasal sinus malignancies were treated with PBT. There were 51 men and 42 women, with median age of 58 years (ranged 17−88). The primary lesions were nasal cavity: 51, maxillary sinus: 15, ethmoid sinus: 14, sphenoid sinus: 7, and others: 6. Various histological types were present, squamous cell carcinoma: 27, olfactory neuroblastoma: 22, malignant melanoma: 18, adenoid cystic carcinoma: 13, and others: 12. T-stage was T2/T3/T4: 14/19/53, and there were 7 patients with recurrent tumors after surgery. PBT was done using 150–190 MeV of proton beam of which the relative biological effectiveness was estimated as 1.1. The optimization of dose distribution was performed with spread-out Bragg peak method. Adverse events were assessed according to the RTOG/EORTC acute and late radiation morbidity scoring criteria. Survivals were estimated by the Kaplan-Meier method.
Results: planned reduction surgery was performed in 24 patients, and induction chemotherapy was given in 18 patients. Median total PBT dose was 65 GyE with 2.5 GyE/fr. With a median follow-up period of 16 months (ranged 2−92), 2-year local control, overall survival, and disease-free survival rates were 78%, 69%, 58%, respectively. liquorrhea and hemorrhage were observed after shrinkage of tumor in one patient each. Cataract, asymptomatic brain necrosis, bone necrosis were developed in 3, 2, 1 patients, respectively. Two patients required surgical soft tissue repair. Visual impairment and other late adverse events equal to or greater than grade 3 were not observed.
Conclusions: The improved conformity of dose delivery by proton beam allows dose escalation leading superior local control and survival rates over those achieved with conventional forms of dose delivery. Toxicity appears acceptable in light of the considerable improvement in local control over conventional therapy.

5520 POSTER

Primary and post-operative radiation therapy for squamous cell carcinoma of the tonsil: a retrospective review of a single institution's experience during the CT simulation era

A.Y. Kee, R.L. Foote, P.D. Brown, Y.I. Garces, S.H. Okuno. *Mayo Clinic Rochester, Radiation Oncology, Rochester Minnesota, USA*

Background: A review of patients with squamous cell carcinoma (SCCa) of the tonsil treated with definitive radiotherapy (RT) ± chemotherapy (C) or postoperative radiotherapy ± C (S+RT±C) during the CT simulation era at Mayo Clinic was performed to determine tumor control, survival, and functional outcome.
Materials & Methods: Between 1989–2004, 114 consecutive patients with SCCa of the tonsil were treated with RT±C (35) or S+RT±C (79). Local control (LC), neck control (NC), survival free of distant metastasis (DM), and overall survival (OS) were evaluated along with late effects of therapy including osteoradionecrosis (ORN), tracheostomy dependency, and percutaneous endoscopic gastrostomy (PEG) dependency.
Results: Median age of patients at diagnosis for the RT±C and S+RT±C group was 57 and 52 years, respectively. 11 patients were treated with RT only, 24 with concurrent C (platinum based) and RT, 78 patients with S+RT, and 1 patient with S+RT+C. In the RT±C, median treatment duration and dose was 43 days and 72 Gy, respectively. Median treatment duration and dose for the postoperative patients was 41 days and 60 Gy. In the definitive radiotherapy group, there was total of 10 patients who underwent neck dissection as part of their treatment either pre RT (3) or post RT (7). There were more advanced T and N stage patients in the RT±C group than the S+RT±C group ($p < 0.001$). Patients treated with RT+C had more advanced local and neck disease compared to RT alone ($p < 0.0001$).
Overall survival and survival free of distant metastasis was better for the S+RT±C group although there was no difference in local or neck control. There was an increased rate of PEG dependancy at last follow up with patients undergoing RT±C. PEG dependency was associated with advanced T stage (T3 & T4, $p = 0.0009$) and the addition of C as part of treatment ($p = 0.007$). There was no significant association between tracheostomy dependency rates or ORN with the type of treatment patients received.

Summary of treatment results

Median Follow Up	RT±CT 42 months	S+RT±CT 67 months	P Value
3 year Local Control	91%	97%	0.12
3 year Neck Control	97%	96%	0.86
3 year Survival Free of DM	78%	93%	0.01
3 year Overall Survival	70%	83%	<0.01
Trach at Last Follow Up	9%	3%	0.15
PEG at Last Follow Up	26%	9%	0.02
ORN at any time	14%	9%	0.51
Surgery for ORN	3%	5%	0.17

Conclusions: Based on our analysis, RT±C provides local and regional control equivalent to S+RT±C even though the disease was more advanced (T and N). Patients with more advanced local or regional disease were more commonly treated with RT±C. This may have led to a higher rate of distant metastasis and lower overall survival compared to the surgery group. Higher rate of PEG dependency was associated with more advanced primary tumors and the addition of chemotherapy to the patient's treatment.

5521 POSTER

The anthology of outcomes: prospective point-of-care outcomes for head and neck cancer patients

J. Ringash[1], S. Huang[2], G. Lockwood[3], A.J. Bayley[1], B.J. Cummings[1], L.A. Dawson[1], J. Kim[1], J. Waldron[1], B. O'Sullivan[1]. *[1]Princess Margaret Hospital, Radiation Oncology, Toronto, Canada; [2]Princess Margaret Hospital, Radiation Medicine, Toronto, Canada; [3]Princess Margaret Hospital, Biostatistics, Toronto, Canada*

Background: The Head and Neck (HN) Radiation Oncology Site Group at our quaternary care comprehensive cancer hospital has established an Anthology of Outcomes (AO) to record outcomes prospectively at point-of-care for all new HN cancer referrals. During each clinic, clinicians indicate the following outcome events: attendance, recurrence (local/regional/distant), second malignancy, and late RTOG grade 3/4 toxicity.
Methods: All patients registered in the AO since July 2003 to Dec 2006 were retrospectively reviewed. Descriptive data, treatment strategy, and vital status were recorded.
Results: Over 3.5 years, 1866 patients were registered; of these, 1763 (F: 504, M: 1259) were treated and followed. Mean age was 62 (range: 15−93) years. Most common cancer diagnoses included: larynx (n = 394), oropharynx 379, oral cavity 357, nasopharynx 156, salivary gland 128, and unknown primary 109. Excluding patients with benign lesions, complex skin cancers and unknown primary cancers, and malignant tumours lacking TNM staging criteria, staging was available for 1585/1622 (98%) patients; 1063/1622 (65%) had advanced disease (stages III/IV), including 26 with distant metastases. Treatment intent was curative in 1688 and palliative in 75. Of patients treated with curative intent, primary surgery was used in 521 (alone, 186; with post-op RT, 284; pre-op RT, 17; post-op chemoradiation [CRT], 34), primary RT in 1167 (alone, 747; CRT 420). The most common RT dose-fractionation schemas were: 70/35 (155 RT alone, 411 CRT), 60/25 (304), 60/30 (162 RT, 18 CRT), 64/40 bid (151), 51/20 (130). IMRT (standard of care since September 2005) was used to treat 860/1577 (54%) radiotherapy patients. At a median follow-up of 16.4 months, 1379 patients (78%) are alive with ongoing follow-up, 160 have died and 224 are no longer being followed by radiation oncology.
Conclusion: Approximately 500 patients per year have been prospectively captured; about 13% are lost to follow-up. The AO allows ongoing quality assurance, rapid feasibility assessment for specific research questions, and represent a resource for outcomes research.

5522 POSTER

Paclitaxel and pegylated liposomal doxorubicin association: effects of different administration intervals on the pharmacokinetics

M. Airoldi[2], L. Cattel[1], P. Milla[1], E. Cerutti[1], F. Pedani[2], A. Crova[2]. *[1]University of Torino, Drug Science and Techn. Dept., Torino, Italy; [2]S. Giovanni Antica Sede Hospital, Medical Oncology, Torino, Italy*

Background: The paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) association is a promising schedule for recurrent head/neck cancer.